Human recombinant EREG promotes cell proliferation in pancreatic [63] and bladder cancer [64] in a dose-dependent manner, whereas an EREG knockdown inhibits tumor growth in hepatocellular carcinoma [65], breast cancer [66], head and neck squamous cell carcinoma (HNSCC) [57], cervical cancer [54], glioma [67], and multiple myeloma [68]. This evidence concerns the gene EREG and head and neck squamous cell carcinoma.